Table 2.
False Discovery Rate Adjusted P Value (q Value) for Each Association Calculated
| Characteristic | P Value | q Value |
|---|---|---|
| Association with on-ART HIV DNA | ||
| Age | .996 | .798 |
| Sex | .783 | .681 |
| Pre-ART HIV RNA | .059 | .112 |
| Pre-ART CD4 T-cell count | .003 | .011 |
| Pre-ART CD8 T-cell count | .013 | .040 |
| Pre-ART CD4/CD8 | .000002 | .00003 |
| Duration of ART | .00001 | .0001 |
| On-ART CD4 T-cell count | .039 | .079 |
| On-ART CD8 T-cell count | .0003 | .002 |
| On-ART CD4/CD8 | .000001 | .00003 |
| Pre-ART IDO activity | .004 | .016 |
| On-ART IDO activity | .00003 | .0003 |
| On-ART IDO activity (CD4 T-cell count <200 cells/μL) | .011 | .037 |
| Pre-ART sCD14 | .556 | .546 |
| Pre-ART LPS | .537 | .546 |
| Pre-ART LBP | .897 | .738 |
| Pre-ART EndoCAb | .546 | .546 |
| Pre-ART sCD163 | .398 | .520 |
| On-ART sCD14 | .348 | .481 |
| On-ART LPS | .461 | .520 |
| On-ART LBP | .783 | .681 |
| On-ART EndoCAb | .897 | .738 |
| On-ART sCD163 | .033 | .072 |
| Percentage of HLA-DR+CD38+ CD4 | .028 | .065 |
| Percentage of HLA-DR+CD38+ CD8 | .026 | .065 |
| Percentage of PD-1+ CD4 | .026 | .065 |
| Percentage of PD-1+ CD8 | .455 | .520 |
| Association with pre-ART IDO activity | ||
| Pre-ART HIV DNA | .601 | .571 |
| Pre-ART HIV RNA | .0002 | .001 |
| Association with on-ART IDO activity | ||
| On-ART sCD14 | .263 | .397 |
| On-ART LPS | .429 | .520 |
| On-ART LBP | .457 | .520 |
| On-ART EndoCAb | .757 | .681 |
| On-ART sCD163 | .274 | .397 |
| Percentage of HLA-DR+CD38+ CD4 | .211 | .337 |
| Percentage of HLA-DR+CD38+ CD8 | .519 | .546 |
| Percentage of PD-1+ CD4 | .083 | .148 |
| Percentage of PD-1+ CD8 | .116 | .196 |
Data in bold indicate significant after adjusted for false discovery rate. False discovery rate <0.05.
Abbreviations: ART, antiretroviral therapy; EndoCAb, endogenous endotoxin-core antibody; HIV, human immunodeficiency virus; HLA-DR, human leukocyte antigen – DR isotype; IDO, indoleamine 2,3-dioxygenase; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; PD-1, programmed cell death 1; sCD14, soluble CD14; sCD163, soluble CD163.